New drug combo shows promise for rare uterine cancer
NCT ID NCT03880019
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This study tests two drugs—olaparib and temozolomide—together in 23 people with advanced uterine leiomyosarcoma that has spread or cannot be removed by surgery. Olaparib blocks a protein that helps cancer cells repair themselves, while temozolomide damages cancer cell DNA. The goal is to see if the combination shrinks tumors better than either drug alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III UTERINE CORPUS LEIOMYOSARCOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
-
Mayo Clinic Hospital in Arizona
Phoenix, Arizona, 85054, United States
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
-
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, New York, 10032, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Stanford Cancer Institute Palo Alto
Palo Alto, California, 94304, United States
-
UCHealth University of Colorado Hospital
Aurora, Colorado, 80045, United States
-
UF Health Cancer Institute - Gainesville
Gainesville, Florida, 32610, United States
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
VCU Massey Comprehensive Cancer Center
Richmond, Virginia, 23298, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
-
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Weisberg Cancer Treatment Center
Farmington Hills, Michigan, 48334, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.